MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination
- PMID: 12798246
- DOI: 10.1016/s0166-0934(03)00128-9
MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination
Abstract
The IgM antibody capture ELISA (MAC-ELISA) and ELISA inhibition methods for the detection of antibodies against dengue virus were modified to detect antibodies against yellow fever virus. Tests were carried out in 21 persons vaccinated with 17D and compared with the Plaque reduction neutralizing test. Of 17 naive subjects vaccinated, 16 (94%) seroconverted using the MAC-ELISA test and 14 (82%) seroconverted (or >/=fourfold titer increase) in the ELISA inhibition method. Cross-reactivity was evaluated by both tests and resulted in a high specificity to IgM antibodies against yellow fever, when all the samples from vaccinated individuals were negative by MAC-ELISA using dengue antigen. However, 10.7% of the positive dengue sera from the Santiago de Cuba epidemic cross-reacted by MAC-ELISA using yellow fever antigen. ELISA inhibition method showed high cross-reactivity when the 21 sera pairs were worked with yellow fever and dengue antigens. The MAC-ELISA and ELISA inhibition methods have become indispensable tools in our laboratory in order to maintain a surveillance system for dengue and dengue hemorrhagic fever. They are relatively rapid, simple, and they do not require sophisticated equipment. Both MAC-ELISA and ELISA inhibition methods for yellow fever could be useful for diagnosis, surveillance and yellow fever vaccine evaluation.
Similar articles
-
Use of MAC-ELISA for evaluation of yellow fever vaccination.Rev Inst Med Trop Sao Paulo. 1992 Sep-Oct;34(5):447-50. doi: 10.1590/s0036-46651992000500012. Rev Inst Med Trop Sao Paulo. 1992. PMID: 1342109
-
[Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].Mikrobiyol Bul. 2010 Jul;44(3):415-24. Mikrobiyol Bul. 2010. PMID: 21063991 Turkish.
-
Evaluation of serological cross-reactivity between yellow fever and other flaviviruses.Int J Infect Dis. 2019 Apr;81:4-5. doi: 10.1016/j.ijid.2019.01.023. Epub 2019 Jan 17. Int J Infect Dis. 2019. PMID: 30660799
-
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.Cell Mol Immunol. 2016 Jan;13(1):36-46. doi: 10.1038/cmi.2015.76. Epub 2015 Oct 5. Cell Mol Immunol. 2016. PMID: 26435066 Free PMC article. Review.
-
Fractional-dose yellow fever vaccination: how much more can we do with less?Curr Opin Infect Dis. 2019 Oct;32(5):390-393. doi: 10.1097/QCO.0000000000000576. Curr Opin Infect Dis. 2019. PMID: 31335440 Review.
Cited by
-
Magnitude of Antibody Cross-Reactivity in Medically Important Mosquito-Borne Flaviviruses: A Systematic Review.Infect Drug Resist. 2021 Oct 19;14:4291-4299. doi: 10.2147/IDR.S336351. eCollection 2021. Infect Drug Resist. 2021. PMID: 34703255 Free PMC article. Review.
-
Diagnosis of dengue virus infection by the visual and simple AuBioDOT immunoglobulin M capture system.Clin Diagn Lab Immunol. 2003 Nov;10(6):1074-7. doi: 10.1128/cdli.10.6.1074-1077.2003. Clin Diagn Lab Immunol. 2003. PMID: 14607869 Free PMC article.
-
Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.J Clin Microbiol. 2018 Sep 25;56(10):e00827-18. doi: 10.1128/JCM.00827-18. Print 2018 Oct. J Clin Microbiol. 2018. PMID: 30021822 Free PMC article. Review.
-
Evaluation of commercially available anti-dengue virus immunoglobulin M tests.Emerg Infect Dis. 2009 Mar;15(3):436-40. doi: 10.3201/eid1503.080923. Emerg Infect Dis. 2009. PMID: 19239758 Free PMC article.
-
Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.Am J Trop Med Hyg. 2013 Sep;89(3):434-44. doi: 10.4269/ajtmh.13-0264. Am J Trop Med Hyg. 2013. PMID: 24006295 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources